

ASX ANNOUNCEMENT 23 FEBRUARY 2022

Successful completion of Institutional Entitlement Offer

Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric** or **Company**) refers to its announcement of 21 February 2022 in relation to an equity raising being undertaken by the Company by way of an accelerated 1 for 3.15 non-renounceable entitlement offer to raise approximately \$18.1 million (before costs of the offer) (**Entitlement Offer**). The Entitlement Offer includes an institutional component (**Institutional Entitlement Offer**) and a retail component (**Retail Entitlement Offer**).

Chimeric is pleased to advise that it has now completed the Institutional Entitlement Offer, raising approximately \$7.37 million. Approximately 43,339,291 fully paid ordinary shares (**New Shares**) at \$0.17 per share (**Offer Price**) together with 43,339,291 attaching options exercisable at \$0.255 and expiring 31 March 2024 (**New Options**) will be issued to successful applicants under the Institutional Entitlement Offer. Executive Chairman, Mr Paul Hopper, took up \$500,000 of his entitlement under the Institutional Entitlement Offer.

New Shares in respect of institutional entitlements not taken up under the Institutional Entitlement Offer and New Shares that would have represented the entitlements of ineligible institutional shareholders were offered to institutional investors.

New Shares issued under the Institutional Entitlement Offer are expected to be issued on 1 March 2022. New Options issued under the Institutional Entitlement Offer will be issued together with New Shares and Options to be issued under the Retail Entitlement Offer on 18 March 2022 (subject to Institutional Shareholders holding at least the number of New Shares they subscribed for under the Institutional Entitlement Offer).

Chimeric shares are expected to resume normal trading on an ex-entitlement basis from the opening of the market today, Wednesday, 23 February 2022.

Commencement of Retail Entitlement Offer

The Retail Entitlement Offer is expected to raise approximately \$10.75 million. The Retail Entitlement Offer will open on 28 February 2022 and is expected to close at 5:00pm (Sydney time) on 11 March 2022.

Under the Retail Entitlement Offer, eligible retail shareholders will be able to subscribe for 1 New Share for every 3.15 existing Chimeric shares (**Entitlement**) held as at 7:00pm (Sydney time) on 23 February 2022 at the Offer Price. Eligible retail shareholders who take up their full Entitlement may also participate in a top-up facility by applying for additional Chimeric shares in excess of their Entitlement at the Offer Price.



Eligible retail shareholders will receive a prospectus, including a personalised entitlement and acceptance form, which will provide further details of how to participate in the Retail Entitlement Offer. A copy of the prospectus was lodged with ASX on 21 February 2022, and will be despatched to eligible retail shareholders on 28 February 2022.